Testing New Lung Cancer Drugs

A unique, collaborative cancer clinical trial that uses genetic screening to match patients to investigational new treatments for non-small cell lung cancers.

Learn More

How it works.

FOR PATIENTS

Patients are assigned to sub-studies using a comprehensive process that looks at over 200 cancer-related genes.

GET THE DETAILS
FOR HEALTHCARE PROVIDERS

Any institution within the National Cancer Institute’s National Clinical Trials Network (NCTN) may open the Lung-MAP study at their site.

GET THE DETAILS

This diverse, collaborative approach, with support from leading lung cancer advocacy organizations, helps to ensure that the needs of patients, clinicians, developers, and regulators are all considered in the design and operation of the trial.

-ELLEN SIGAL, PH.D. Chair and Founder, Friends of Cancer Research

View Our Partners

Find a location

The trial is open at a nework of cancer centers, community hospitals, academic medical centers, and physican cooperatives across the United States with operations being managed by SWOG Cancer Research within the National Cancer Institute’s National Clinical Trials Network.

News & Media

Press
29
Jan
2019

The Lung Cancer Master Protocol (Lung-MAP), the first precision medicine trial in lung cancer supported by the National Cancer Institute (NCI),...